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Abstract
Aims/hypothesis Type 2 diabetes is regarded as inevitably
progressive, with irreversible beta cell failure. The hypoth-
esis was tested that both beta cell failure and insulin
resistance can be reversed by dietary restriction of energy
intake.
Methods Eleven people with type 2 diabetes (49.5±
2.5 years, BMI 33.6±1.2 kg/m2, nine male and two female)
were studied before and after 1, 4 and 8 weeks of a 2.5 MJ
(600 kcal)/day diet. Basal hepatic glucose output, hepatic
and peripheral insulin sensitivity and beta cell function
were measured. Pancreas and liver triacylglycerol content
was measured using three-point Dixon magnetic resonance
imaging. An age-, sex- and weight-matched group of eight
non-diabetic participants was studied.
Results After 1 week of restricted energy intake, fasting
plasma glucose normalised in the diabetic group (from 9.2±
0.4 to 5.9±0.4 mmol/l; p=0.003). Insulin suppression of
hepatic glucose output improved from 43±4% to 74±5% (p=
0.003 vs baseline; controls 68±5%). Hepatic triacylglycerol
content fell from 12.8±2.4% in the diabetic group to 2.9±
0.2% by week 8 (p=0.003). The first-phase insulin response
increased during the study period (0.19±0.02 to 0.46±
0.07 nmol min−1 m−2; p<0.001) and approached control
values (0.62±0.15 nmol min−1 m−2; p=0.42). Maximal
insulin response became supranormal at 8 weeks (1.37±
0.27 vs controls 1.15±0.18 nmol min−1 m−2). Pancreatic
triacylglycerol decreased from 8.0±1.6% to 6.2±1.1%
(p=0.03).
Conclusions/interpretation Normalisation of both beta cell
function and hepatic insulin sensitivity in type 2 diabetes was
achieved by dietary energy restriction alone. This was
associated with decreased pancreatic and liver triacylglycerol
stores. The abnormalities underlying type 2 diabetes are
reversible by reducing dietary energy intake.
Keywords Insulin secretion . Liver fat . Low energy diet .
Pancreatic fat . Type 2 diabetes
Abbreviation
ffm Fat-free mass
Introduction
Type 2 diabetes has long been regarded as a chronic
progressive condition, capable of amelioration but not cure.
A steady rise in plasma glucose occurs irrespective of the
degree of control or type of treatment [1]. Beta cell function
declines linearly with time, and after 10 years more than
50% of individuals require insulin therapy [2]. The
underlying changes in beta cell function have been well
described [3, 4], and beta-cell mass decreases steadily
during the course of type 2 diabetes [5, 6]. Overall, there is
strong evidence that type 2 diabetes is inexorably progressive,
with a high likelihood of insulin therapy being eventually
required to maintain good glycaemic control.
However, type 2 diabetes is clearly reversible following
bariatric surgery [7]. The normalisation of plasma glucose
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concentration follows within days of surgery, long before
major weight loss has occurred, and it has become widely
assumed that the protective effects of gastrointestinal
surgery are mediated by altered secretion of incretin
hormones [8, 9]. Improved control of blood glucose in
type 2 diabetes by moderate energy restriction has been
demonstrated by others [10]. We have hypothesised that the
profound effect of a sudden negative energy balance on the
metabolism could explain the post-bariatric surgery effect
[11] and, specifically, that the decrease in the intracellular
fatty acid concentrations in the liver would lead to a lower
export of lipoprotein triacylglycerol to the pancreas, with
the release of beta cells from the chronic inhibitory effects
of excess fatty acid exposure.
This study was designed to test the hypothesis that acute
negative energy balance alone reverses type 2 diabetes by
normalising both beta cell function and insulin sensitivity.
We examined the restoration of first-phase and total insulin
response as well as hepatic and peripheral insulin sensitiv-
ity. Additionally, to examine the mechanistic basis of
observed outcomes, we quantified the change in fat content
of the pancreas and liver.
Methods
Participants Individuals with type 2 diabetes (age 35–
65 years, HbA1c 6.5–9.0% [48–75 mmol/mol], diabetes
duration <4 years, stable BMI 25–45 kg/m2) were recruited.
Participants were excluded if being treated with thiazolidine-
diones, insulin, steroids or beta-blockers, with a serum
creatinine >150 mmol/l, with a serum alanine transaminase
level >2.5-fold above the upper limit of the reference range,
or if there were contraindications for MRI. Statin therapy
was continued. The study protocol was approved by the
Newcastle upon Tyne Ethics Committee No. 2, and all
participants gave their informed consent. Sulfonylurea (two
individuals) was discontinued 2 months, and metformin
(seven individuals) 1 week, before the baseline study. Dietary
adherence was assessed using capillary ketone levels (Xceed
Optium; Abbott Diabetes Care, Maidenhead, UK). Three
individuals failed to comply with the diet (two during the first
week and one during weeks 4–8), and one left the study for
an unrelated medical reason. Hence 11 individuals (nine male
and two female, age 49.5±2.5 years) completed the study.
Nine control participants matched for weight, age and sex
were also studied (sevenmale, two female, age 49.7±2.5 years;
Table 1). These participants had no family history of diabetes,
were taking no medication and had normal glucose
metabolism as confirmed by a standard 75 g OGTT.
Experimental protocol Participants were asked to continue
their habitual pattern of eating until the start of the study.
Assessments of beta cell function, insulin sensitivity, liver
and pancreatic fat content and total body fat were carried
out at baseline immediately prior to dietary intervention
(day −1), and after 1, 4 and 8 weeks of the very-low-energy
diet. A group of matched non-diabetic controls were
studied on one occasion only, without dietary intervention.
After the baseline measurements, individuals with type 2
diabetes started the diet, which consisted of a liquid diet
formula (46.4% carbohydrate, 32.5% protein and 20.1%
fat; vitamins, minerals and trace elements; 2.1 MJ/day
[510 kcal/day]; Optifast; Nestlé Nutrition, Croydon, UK).
This was supplemented with three portions of non-starchy
vegetables such that total energy intake was about 2.5 MJ
(600 kcal)/day. Participants were provided with sugges-
tions of vegetable recipes to enhance compliance by
varying daily eating. They were also encouraged to drink
at least 2 l of water or other energy-free beverages each
day, and asked to maintain their habitual level of
physical activity. Ongoing support and encouragement
was provided by means of regular telephone contact. At
the end of the 8 week intervention participants returned
to normal eating but were provided with information
about portion size and healthy eating.
The striking results seen at 8 weeks demanded experi-
mental follow-up, and additional ethics permission was
obtained to repeat the MRI studies and carry out OGTTs
12 weeks after completing the dietary intervention.
Hepatic glucose production and insulin sensitivity After an
overnight fast, cannulae were inserted into an antecubital vein
for infusion and the contralateral wrist vein for arterialised
Variable Controls Baseline Week 1 Week 4 Week 8
Weight (kg) 101.5±3.4 103.7±4.5 99.7±4.5* 94.1±4.3* 88.4±4.3*†
BMI (kg/m2) 33.4±0.9 33.6±1.2 32.3±1.2* 30.5±1.2* 28.7±1.3*†
Fat mass (kg) 36.2±2.7 39.0±3.5 36.6±3.6* 31.7±3.7* 26.3±4.0*
ffm (kg) 64.7±3.8 64.7±3.0 63.2±3.1 62.4±3.0* 62.1±3.0*
Waist circumference (cm) 105.0±1.5 107.4±2.2 104.4±2.2* 99.7±2.4* 94.2±2.5*†
Hip circumference (cm) 109.8±2.4 109.5±2.9 108.3±2.7* 105.0±2.6* 99.5±2.6*†
WHR 0.96±0.02 0.98±0.02 0.97±0.02 0.95±0.01 0.95±0.01
Table 1 Anthropometric data
before and during the 8 weeks
of dietary intervention in com-
parison with control individuals
Data are mean ± SE
†p<0.05 individuals with type 2
diabetes vs controls; *p<0.05
type 2 diabetes baseline vs later
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blood sampling. [6′6′-2H]glucose (98% enriched; Cambridge
Isotope Laboratories, Andover, MA, USA) was used to
determine hepatic glucose production [12, 13], and basal
rates were calculated during the last 30 min of the 150 min
basal period. Preinfusion enrichment of isotope was insig-
nificant throughout. An isoglycaemic–hyperinsulinaemic
clamp (insulin infusion rate 40 mU m−2 min−1) was initiated
at 0 min [14]. Isoglycaemia was used to ensure that the true
fasting condition of each participant could be observed at
each study time point. Each participant was clamped at the
glucose level observed at the end of the basal period.
Whole-body insulin sensitivity was determined during
the last 30 min of the hyperinsulinaemic glucose clamp
as whole-body glucose disposal corrected for glucose
space and urinary loss [14, 15]. Glucose metabolic
clearance rates during steady-state conditions were calculated
by dividing whole-body insulin sensitivity by steady-state
plasma glucose.
Assessment of beta cell function Sixty minutes after the
clamp test, two consecutive 30 min square-wave steps of
hyperglycaemia (2.8 and 5.6 mmol/l above baseline) were
achieved by a priming glucose dose followed by variable
20% glucose infusion [16]. Blood samples for determina-
tion of plasma glucose, insulin and C-peptide concentra-
tions were obtained every 2 min for the first 10 min and
every 5 min for the other 20 min of each step. An arginine
bolus was administered during the second step of hyper-
glycaemia, followed by sampling every 2 min for 10 min.
Insulin secretion rate was calculated using a computerised
program implementing a regularisation method of decon-
volution [17] and using a population model of C-peptide
kinetics [18].
Magnetic resonance measurements A Philips 3.0 T
Achieva scanner and six-channel cardiac coil (Philips
Healthcare, Best, the Netherlands) were used to acquire
three gradient-echo scans with adjacent out-of-phase and
in-phase echoes (time to repetition/time to echo/averages/
flip angle=50 ms/3.45, 4.60, 5.75 ms/1/30°, matrix 160×
109, field of view 400–480 mm to suit participant size with
70% phase field of view). Six slices were acquired within a
17 s breath-hold to cover the liver with slice thickness
10 mm and the pancreas with slice thickness 5 mm. The
data were analysed in MATLAB (MathWorks, Cambridge,
UK) to produce separate fat and water images [19]. The fat
content of the image was expressed as a percentage of the
total signal per voxel. The intraorgan fat percentage was
evaluated from five liver regions of interest and two
pancreatic regions of interest, defined and averaged in a
blinded fashion by one observer (K. G. Hollingsworth). The
pancreatic fat data represent solely intrapancreatic fat, and
the liver data avoid contamination from blood vessels and
gallbladder. This was achievable because of the data
processing after image acquisition, allowing manual selection
of wholly intraorgan volume from the anatomical slice. The
interscan Bland–Altman repeatability coefficients were 0.5%
for the liver and 0.9% for the pancreas.
Body composition and anthropometry Percentage body fat
was measured following an overnight fast using air-
displacement plethysmography (BOD POD Express; Life
Measurement, Concord, CA, USA). Waist and hip circum-
ferences were measured with the participants in a relaxed
standing posture. Waist circumference was taken at the
mid-point between the anterior superior iliac spine and
the lower edge of the rib cage, and hip circumference at
the level of the greater trochanter. All measurements
were made throughout the study period by a single
observer (E. L. Lim).
Analytical procedures Plasma glucose concentration was
measured by the glucose oxidase method (YSI glucose
analyser; Yellow Springs, OH, USA), plasma insulin and C-
peptide concentrations by ELISA (Dako, Ely, UK), plasma
triacylglycerol by lipase with released glycerol measured by a
Roche Cobas centrifugal analyser using a colorimetric assay
(ABX Diagnostics, Montpellier, France) and HbA1c by a
Biorad HPLC (TOSOH Corporation, Tokyo, Japan). 2H
atom percent excess in plasma glucose was determined using
a Thermo ‘Voyager’ single quadrupole mass spectrometer
with Thermo ‘Trace’ gas chromatograph (Thermo Scientific,
Waltham, MA, USA).
Statistical methods Statistical analyses were performed
using SPSS 17.0 software (SPSS Inc., Chicago, IL,
USA). Data are presented as mean ± SE. Statistical
comparisons between diabetes and control groups were
performed using the Student’s t test, while within-group
differences were determined using a paired t test. Changes
of sequential data within experiments were evaluated by
repeated measures one-way ANOVA with post hoc Bonfer-
roni testing where appropriate. Correlations were examined
using the Spearman rank test. Statistical significance was
accepted at p<0.05.
Results
Plasma glucose and insulin After 1 week of dietary
intervention, fasting plasma glucose decreased from 9.2±
0.4 to 5.9±0.4 mmol/l (p=0.003; Fig. 1) and was not
significantly different from that of the non-diabetic control
group (5.3±0.1 mmol/l; p=0.18). It remained stable for the
rest of the 8 week study (5.7±0.5 mmol/l at weeks 4 and 8;
p=0.52 compared with control). HbA1c decreased from
2508 Diabetologia (2011) 54:2506–2514
7.4±0.3% (57±3 mmol/mol) and at 8 weeks was not
significantly different from non-diabetic control values
(6.0±0.2 vs 5.7±0.1% [42±2 vs 39±1 mmol/mol], p=
0.27) Fasting plasma insulin fell from 151±31 to 73±10
pmol/l after 1 week (p=0.03) and to 65±15 pmol/l by
8 weeks (p=0.03 vs baseline; p=0.04 vs control). Fasting
plasma C-peptide decreased similarly (Table 2).
During the isoglycaemic clamp, plasma glucose was
clamped at 4.6±0.1 mmol/l in the control group
compared with 7.0±0.3 mmol/l in the diabetes group at
baseline (p<0.001). At week 1, the achieved clamped
plasma glucose level was 4.8±0.2 mmol/l (p<0.001 vs
baseline) in the diabetes individuals and this was similar at
weeks 4 and 8 (4.8±0.3 and 4.8±0.4, respectively, p<
0.001 vs baseline).
Hepatic insulin sensitivity and hepatic triacylglycerol
content Basal hepatic glucose production decreased signifi-
cantly during the first week of energy restriction (2.40±0.28
to 1.59±0.07mg kgffm
−1min−1; p=0.05), remained decreased
compared with baseline for the rest of the study, and at
8 weeks was not significantly different from that of the
control group (1.71±0.11 vs 2.11±0.22 mg kgffm
−1min−1
respectively; p=0.60; Fig. 1). At baseline, hepatic insulin
sensitivity, assessed by the suppression of hepatic glucose
production by insulin infusion, was 43±4% in the diabetic
group compared with 68±5% in the control group
(p=0.001). During the first week of energy restriction, there
was a marked improvement in hepatic insulin responsive-
ness, with insulin suppression of hepatic glucose production
increasing to 74±5% (p=0.003 vs baseline).
Hepatic triacylglycerol content decreased by 30±5%
during week 1 of intervention (p<0.001), becoming similar
to control values (p=0.75). It continued to decline
throughout the intervention period to reach the normal
range for non-obese individuals [20] (2.9±0.2%; p=0.003;
Fig. 1), i.e. a total reduction of 70±5%. At baseline, hepatic
triacylglycerol content was 8.5±1.9% in the control group
compared with 12.8±2.4% in the diabetic group (p=0.14).
Hepatic triacylglycerol at baseline correlated with BMI in
Fig. 1 Effect of 8 weeks of dietary intervention on (a) plasma
glucose, (b) hepatic glucose production (HGP) and (c) hepatic
triacylglycerol content (TG) for diabetic participants (black triangles).
White circles indicate the mean for the weight-matched non-diabetic
control group. Data are shown as mean ± SE
Table 2 Metabolic response to 8 weeks of dietary intervention in participants with type 2 diabetes in comparison with controls
Fasting concentration Controls Baseline Week 1 Week 4 Week 8
HbA1c (%) 5.7±0.1 7.4±0.3
†† 7.1±0.3*†† 6.5±0.2**† 6.0±0.2**
HbA1c (mmol/mol) 39±1 57±3
†† 55±3*† 47±3**† 42±2**
Plasma glucose (mmol/l) 5.3±0.1 9.2±0.4†† 5.9±0.4** 5.7±0.6** 5.7±0.5**
Plasma insulin (pmol/l) 115±27 151±31 73±10* 57±11* 65±15*†
Plasma C-peptide (nmol/l) 1.06±0.12 1.21±0.20 1.14±0.16 1.19±0.19 0.86±0.11
Triacylglycerol (mmol/l) 1.8±0.1 2.4±0.5 1.2±0.1*† 1.0±0.1*†† 1.3±0.3*†
NEFA (mmol/l) 0.57±0.07 0.69±0.06 0.93±0.05*†† 0.81±0.08† 0.72±0.06
Cholesterol (mmol/l) 5.1±0.3 4.0±0.3† 3.3±0.3*†† 2.8±0.2*†† 3.2±0.3††
LDL-cholesterol (mmol/l) 3.2±0.3 1.7±0.2†† 1.8±0.4†† 1.0±0.2*†† 1.3±0.2††
HDL-cholesterol (mmol/l) 1.1±0.1 1.1±0.1 1.0±0.1 1.1±0.1 1.1±0.1
ALT (U/l) 33±3 46±7 61±10*† 44±3† 33±3
Gamma GT (U/l) 39±5 62±12 49±8 25±4† 26±5**
Data are mean ± SE
† p<0.05 vs controls; †† p<0.005 vs controls; * p<0.05 vs type 2 diabetes baseline; ** p<0.005 vs type 2 diabetes baseline
ALT, alanine transaminase; gamma GT, γ-glutamyltransferase
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the controls (Rs=0.71; p<0.05) but not in the diabetic
group (Rs=−0.50; p=0.12).
Beta cell sensitivity to glucose and pancreas triacylglycerol
content Fasting insulin secretion rate decreased from 0.10±
0.01 to 0.06±0.01 nmol min−1 m−2 during the first week
(p<0.05) and remained constant thereafter. During the
insulin secretion test, the planned step increases in plasma
glucose concentration of +2.8 and +5.6 mmol/l were
achieved (Fig. 2). In the diabetes individuals, peak insulin
secretion rate at 6 min was minimal at baseline (0.19±0.02
vs control 0.62±0.15 nmol min−1 m−2; p<0.001; Fig. 2).
The first-phase insulin response steadily increased and was
significantly different from baseline by 8 weeks (0.29±
0.05, 0.34±0.06 and 0.46±0.07 nmol min−1 m−2 at 1, 4 and
8 weeks; p=0.20, p=0.09, p=0.006, respectively). At
8 weeks in the individuals with type 2 diabetes, the insulin
secretion rate was not significantly different from control
(0.46±0.07 vs 0.62±0.15 nmol min−1 m−2; p=0.42). There
was an increase in arginine-induced insulin response after
1 week (from 0.72±0.11 to 0.95±0.19 nmol min−1 m−2;
p<0.006), and by 8 weeks it was completely normalised
(1.37±0.27 vs 1.15±0.18 nmol min−1 m−2; p=0.77 vs
control; p<0.03 vs baseline; Fig. 2). It was 38% lower
in the participants with type 2 diabetes at baseline
compared with the controls (0.72±0.11 vs 1.15±
0.18 nmol min−1 m−2; p=0.04).
Pancreatic triacylglycerol content in the diabetic group was
8.0±1.6% and fell steadily to 6.2±1.1% after 8weeks (p=0.03;
Fig. 3). In control individuals, pancreatic triacylglycerol
content was 6.0±1.3% (p=0.17 compared with participants
with type 2 diabetes at baseline). There was no correlation
with BMI in either the control or the diabetic group (Rs=0.31,
p=0.36; Rs=0.01, p=0.98, respectively).
Peripheral insulin sensitivity There was no significant change
in peripheral insulin sensitivity expressed as glucose disposal
rates during the entire study. Insulin-stimulated glucose
Fig. 2 Insulin secretion test
data in controls and in diabetic
participants at each time point. a
Plasma glucose levels achieved
in each group. Insulin section
rate (ISR) obtained in (b) the
non-diabetic control group, (c)
the diabetic group at baseline,
(d) the diabetic group at 1 week
of the diet, (e) the diabetic group
at 4 weeks and (f) the diabetic
group at 8 weeks. Data are
shown as mean ± SE
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disposal was 3.83±0.23 and 4.36±0.36 mg kgffm
−1min−1
(where ffm is fat-free mass) at baseline and 8 weeks,
respectively (p=0.21). Change in glucose metabolic clear-
ance rate was examined to correct for the difference in clamp
glucose levels between study days. Fasting plasma glucose
decreased between baseline and week 1. There was no
significant effect of the dietary intervention on glucose
metabolic clearance rate at either 1 or 4 weeks (3.1±0.3 vs
4.23±0.34 and 4.21±0.36 ml kgffm
−1min−1, respectively),
but improvement was demonstrable by week 8 (5.2±
0.5 ml kgffm
−1min−1; p=0.003 for baseline vs 8 weeks;
control group 5.2±0.4 ml kgffm
−1min−1; p=0.98).
Weight and body composition Average weight loss during
the 8 weeks of dietary intervention was 15.3±1.2 kg,
equivalent to 15±1% of initial body weight (Table 1).
Weight loss was 3.9±0.2 kg during the first week (61% of
which was fat loss), 5.7±0.6 kg (86% as fat) between
weeks 1 and 4, and 5.7±0.7 kg (94% as fat) during the final
4 weeks. Both waist and hip circumference decreased to the
same extent and WHR remained unchanged during the
8 weeks (Table 1).
Plasma lipids Plasma triacylglycerol levels halved during
the first week of dietary energy restriction (2.4±0.5 to 1.2±
0.1 mmol/l; p<0.02) and remained constant thereafter
(Table 2). Total cholesterol also decreased, and HDL-
cholesterol remained unchanged during the study period
(Table 2). Fasting plasma NEFA levels were modestly but
not significantly higher in the diabetic participants
compared with the matched controls at baseline (0.69±
0.06 vs 0.57±0.07 mmol/l; p=0.24). During the study
period, fasting NEFA in the participants with diabetes
increased significantly at week 1 (0.93±0.05 mmol/l;
p=0.03 vs baseline). With continued hypoenergetic intake,
plasma NEFA declined steadily towards baseline values
(0.81±0.08 and 0.72±0.06 mmol/l at weeks 4 and 8,
respectively).
Post-intervention observation At follow-up 12 weeks after
completion of the dietary intervention, mean weight gain was
3.1±1.0 kg. Hepatic triacylglycerol remained low and un-
changed (2.9±0.2 vs 3.0±0.3%; p=0.80), and pancreatic
triacylglycerol decreased further to a small extent (6.2±1.1 vs
5.7±1.1%; p=0.005). HbA1c was unchanged (6.0±0.2 vs
6.2±0.1% [42±2 vs 44±1 mmol/mol]; p=0.10) and fasting
plasma glucose increased modestly (5.7±0.5 vs 6.1±
0.2 mmol/l; p<0.01), with a 2 h OGTT plasma glucose of
10.3±1.0 mmol/l. Three participants had recurrence of
diabetes as judged by a 2 h post-load plasma glucose
>11.1 mmol/l. Fasting plasma insulin concentrations were
unchanged (57±11 vs 65±15 pmol/l) and fasting plasma
NEFA decreased further (0.72±0.06 vs 0.54±0.05 mmol/l;
p<0.02). One individual was unavailable for retesting, having
had surgery for an ovarian cyst (non-malignant).
Discussion
This study demonstrates that the twin defects of beta cell
failure and insulin resistance that underlie type 2 diabetes
can be reversed by acute negative energy balance alone. A
hierarchy of response was observed, with a very early
change in hepatic insulin sensitivity and a slower change in
beta cell function. In the first 7 days of the reduced energy
intake, fasting blood glucose and hepatic insulin sensitivity
fell to normal, and intrahepatic lipid decreased by 30%.
Over the 8 weeks of dietary energy restriction, beta cell
function increased towards normal and pancreatic fat
decreased. Following the intervention, participants gained
3.1±1.0 kg body weight over 12 weeks, but their HbA1c
remained steady while the fat content of both pancreas and
liver did not increase. The data are consistent with the
hypothesis that the abnormalities of insulin secretion and
insulin resistance that underlie type 2 diabetes have a
single, common aetiology, i.e. excess lipid accumulation in
the liver and pancreas [11]. This provides a unified
hypothesis to explain a common disease that previously
Fig. 3 a Change in first-phase insulin response, and (b) change in
pancreas triacylglycerol (TG) content during the 8 week dietary
intervention in diabetic individuals (black triangles). White circles
indicate the mean for the weight-matched non-diabetic control group.
Data are shown as mean ± SE
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appeared to require separate disease processes affecting the
pancreas and insulin-sensitive tissues.
Absence of rapid insulin secretion in response to a rise in
plasma glucose is the hallmark of type 2 diabetes [3, 21],
and the decline in beta cell function determines the
progression towards a need for insulin therapy [2].
However, conventional therapy, even with sulfonylurea,
fails to produce more than a small increase in the first-phase
insulin response. As a consequence, the rapidity and extent
of return of beta cell function in response to dietary energy
restriction in the present study is striking. It supports the
accumulating information on the inhibitory effect of fatty
acids on insulin secretion in vitro and in vivo [22–24] and is
the first direct evidence in humans that the beta cell defect of
type 2 diabetes is reversible by sustained negative energy
balance. Prolonged elevation of plasma fatty acids in humans
decreases insulin secretion [25, 26], and it has previously
been shown that there is an association between pancreatic
fat content and type 2 diabetes [27–29]. Prior to the onset of
spontaneous diabetes in rodents, both total pancreatic fat and
islet triacylglycerol content increase sharply [30, 31]. In
vitro, chronic saturated fatty acid exposure of beta cells
inhibits the acute insulin response to glucose, and removal of
fatty acids allows recovery of this response [32].
The present data provide clear evidence that decreasing
total pancreatic fat is associated with a return of beta cell
function. However, it is probable that the negative effect on
beta cell function is exerted by toxic intermediaries such as
diacylglycerol and ceramides, which change rapidly in
response to acute metabolic changes [33], rather than by
stored triacylglycerol per se, which acts as an index of fatty
acid intermediary concentration. There was no correlation
between indices of insulin secretion and pancreatic fat,
which suggests that there are individual thresholds of
tolerance for such toxic intermediaries rather than a simple
dose–response relationship within the pancreas.
Fasting plasma glucose concentration is determined by
the rate of hepatic glucose production, and hepatic insulin
sensitivity is inversely proportional to intrahepatic lipid
content [13, 34–36]. Moderate weight loss has previously
been shown to be associated with a fall in intrahepatic fat
content [10, 37]. Petersen et al. have previously reported
improved liver and no significant change in muscle insulin
sensitivity measured by euglycaemic hyperinsulinaemic
clamps after 8 weeks of moderate energy restriction in
type 2 diabetes [10]. A very low energy intake has been
observed to lower liver fat content in healthy obese
individuals within days [38]. The present study demon-
strates for the first time the early time course with which
both hepatic fat stores and hepatic glucose production fall
in response to dietary restriction in type 2 diabetes. Change
in peripheral insulin sensitivity played no part in the early
return of normoglycaemia. It is possible that the sharp rise
in plasma NEFA observed after 1 week of the hypocaloric
diet could have prevented a change in peripheral insulin
sensitivity even though this did not prevent the rapid
improvement of hepatic insulin sensitivity.
We have previously hypothesised that establishing the
pathophysiological changes that accompany the reversal of
type 2 diabetes will illuminate the sequence of changes
determining the onset of the disease [11]. This twin-cycle
hypothesis was informed by observations following bari-
atric surgery, especially the demonstration that fasting
blood glucose concentrations fell within days after bilio-
pancreatic diversion [39]. As these changes occur before
substantial weight loss, it has become widely accepted that
bariatric surgery exerts such rapid effects by changes in
incretin hormones. However, the extent of change in
incretins is modest, not always present in type 2 diabetes,
and absent after gastric banding [40–43]. Little attention
has been paid to the potential role of a sudden negative
energy balance on glucose metabolism after bariatric
surgery, although a recent small study suggested that the
improvement in insulin resistance in the first week after
surgery can be attributed to negative energy balance alone
[44]. Increased glucagon-like peptide-1 secretion following
bariatric surgery compared with a hypocaloric diet has been
reported, but the oral glucose load used in the presence of a
gastroenterostomy is likely to explain the early rapid rise in
both plasma glucose and the incretin, occasionally with the
symptoms of early dumping [45].
The limitations of this study must be considered. First, the
sample size was necessarily small to allow the application of
gold standard methods for metabolic investigation and
examination by magnetic resonance techniques. However,
the participants were drawn from the population with type 2
diabetes, and their clinical and anthropometric characteristics
were typical for the condition.
Second, pancreatic fat measurements included intraorgan
adipocyte fat content because current methodology pre-
cludes the assessment of the more mechanistically impor-
tant islet intracellular fatty acid content. Animal data
suggest that the two variables are linked [31]. Although
pancreatic fat content was 30% higher in the diabetic group,
the study was powered to demonstrate responses to the
dietary intervention rather than to test differences from
weight-matched non-diabetic individuals. No correlation
was observed between pancreatic fat and BMI within the
restricted range of BMI examined in this study.
Third, the participants were selected to have had a
relatively short duration of type 2 diabetes (up to 4 years),
and further studies must establish the extent of reversibility
with longer duration type 2 diabetes. In addition, further
studies are required to determine the long-term outcome in
respect of glucose regulation as the observations made after
12 weeks of return to a normal diet were necessarily limited.
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Finally, the raised liver fat levels despite metabolic
normality in some controls can be considered in the light of
the recent description of the PNPLA3 gene [46]. The
G allele of this gene determines high liver fat levels, but in
a form that is not associated with metabolic abnormality.
This provides a clear genetic basis for the observed
individual variation in susceptibility to insulin resistance
despite raised liver fat content, and offers a partial
explanation of the overlapping hepatic fat levels in type 2
diabetic and control groups. It is likely that other genetic
factors yet to be defined underlie the differing individual
levels of susceptibility to pancreatic fat accumulation in
terms of inhibition of glucose-dependent insulin secretion.
This study demonstrates for the first time the time
course of a return of normal beta cell function and
hepatic glucose output by acute restriction of dietary
energy intake in individuals with type 2 diabetes. The
changes occurred in association with decreases in
pancreatic and liver triacylglycerol concentrations. This
new insight allows an understanding of the causality of
type 2 diabetes in individuals as well as in populations. It
carries major implications for information to be given to
newly diagnosed patients, who should know that they
have a potentially reversible condition and not one that is
inevitably progressive.
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